The trusted source for information on cancer built in collaboration with millions of patients and the country's leading academic medical centers.
New York City
Joined April 2018
- Tweets4K
- Following2.2K
- Followers2.8K
- Likes4.5K
SurvivorNet retweeted
Patient reported outcomes matter - and we need them to be easy for everyone to use
Among patients with metastatic #BreastCancer, alert-based digital patient-reported outcome monitoring was associated with lower fatigue at 6 months vs usual care, with improvement exceeding the minimal clinically important difference.
ja.ma/4hRo6Ly
SurvivorNet retweeted
This update which I do every 1-2 years is has usually been the most downloaded paper in AJH.
Free Access: My 2026 update on diagnosis, risk stratification, treatment, and prognosis of multiple myeloma.
Link: onlinelibrary.wiley.com/doi/… @AjHematology
Algorithms. 10 Tables!
Bookmark!
SurvivorNet retweeted
Mayo Clinic’s Radiomics-Based Early Detection Model (REDMOD) has been named one of @TIME's Best Inventions of 2026, recognizing an innovative approach to detecting pancreatic cancer earlier.
REDMOD uses AI to analyze CT scans for subtle changes in pancreatic tissue texture that may be detectable up to three years before a pancreatic cancer diagnosis.
With support from the Hoveida Family Foundation and high-performance graphics processing unit (GPU) technology from @nvidia, a multidisciplinary team at @MayoCancerCare is advancing an innovation with the potential to transform pancreatic cancer detection.
See TIME’s full list of the Best Inventions of 2026: ti.me/best-inventions | #TIMEBestInventions
SurvivorNet retweeted
We are saddened by the passing of Rachna T. Shroff, MD, MS, a renowned physician-scientist who treated people with pancreatic cancer and advanced treatment options for patients facing pancreatic and hepatobiliary cancers. Dr. Shroff passed away following a battle with an aggressive cancer. She was 47.
Through her groundbreaking research and leadership in clinical trials, Dr. Shroff helped move the field forward and expand possibilities for patients. She also collaborated with PanCAN on research related to our Know Your Tumor® precision medicine service, contributing to a deeper understanding of pancreatic cancer.
We extend our heartfelt condolences to her loved ones, colleagues and the many patients whose lives she touched. 💜
Read more from the @UAZMedTucson at 🔗 bit.ly/4jprjTS.
SurvivorNet retweeted
GI oncology is a small world, and we were so fortunate to have you in it, Rachna. Your legacy lives on through the mentees you nurtured, the colleagues you inspired, and the lives you touched and saved. Your impact will be felt for generations. You will be deeply missed ❤️@ASCO
We join the oncology community in mourning the passing of Dr. Rachna T. Shroff, a renowned GI cancers expert and a dedicated ASCO volunteer. We are humbled by her dedication and strive to honor her legacy of commitment and altruism.
Read more: bit.ly/4e7jBKu
SurvivorNet retweeted
Absolutely heartbreaking! I did not know her but what an incredible person and accomplished physician- a true pioneer in her field. We all mourn her loss!
👉We deeply mourn the loss of our dear friend, loving big sister, co-fellow, world expert, the brilliant light, amazing all-time Dr .@rachnatshroff | May she rest in peace. May her wonderful legacy carry on forever, may we never forget @rachnatshroff 🙏
medicine.arizona.edu/news/20…
SurvivorNet retweeted
NBC's @TODAYshow highlights Dr. Rachna Shroff's cancer journey, honoring her life, clinical impact, and legacy in supporting the next generation of researchers.
today.com/health/disease/rac…
Thank you @UCCancerCenter for helping so many patients and helping us bitter inform the community. Keep going!!
Continuous research drives real progress in cancer care.
@FDA approved Tucatinib maintenance for advanced HER2+ breast cancer delayed cancer progression by a median 8.6 months in clinical trials.
#BreastCancerResearch
@UChicagoBreast @SurvivorNetTeam
ow.ly/u5x150ZXFGY
SurvivorNet retweeted
Beyond devastating. Rachna was a friend to all oncologists, well known in @ASCO circles. We will all miss her. Her legacy lives on in the YIA endowed in her name.
@DrChoueiri @montypal @ERPlimackMD @aparna1024 @ErikaHamilton9
medicine.arizona.edu/news/20…
For many breast cancer survivors, the end of treatment brings a new chapter, with its own questions and uncertainties. As appointments slow down, the “what if it comes back?” thoughts can move in.
That’s why SurvivorNet continues to offer expert guidance, survivor stories, and resources at every step—helping patients feel informed and supported as they navigate life after treatment.
survivornet.com/articles/not…
SurvivorNet retweeted
If a healthcare provider says “you’re too young for cancer”, get a new doctor/NP/PA.
The incidence of breast cancer in young women is increasing. It’s salt in the wound when concerns are dismissed and when finally someone listens, the cancer has already metastasized.
Day 10 - Breast Cancer Under 40
Breast cancer is the most common cancer in women aged 15–39, with 250,000 young women in the U.S. living with a diagnosis today. Younger patients are more often diagnosed late stage.
There is no such thing as too young for MBC.
#metavivor #METober
SurvivorNet retweeted
Exciting developments happening in ES-SCLC.
With steep attrition across lines of therapy, optimizing 1L Tx is critical. Lurbinectedin has moved into 1L maintenance. Tarlatamab and DLL3, B7-H3, and SEZ6 ADCs are being evaluated in 1L. Great talk by @LauraAlderMD!
SurvivorNet retweeted
Do you know how we got to this remarkable place for HER2+ breast cancer? Research.
And may research bring these same results to all subtypes.
You can support @metavivor’s research by donating…. until no one dies from MBC.
We’ve long treated HER2+ breast cancer similarly. Until everything changed.
Within 1 year, T-DXd moved earlier, palbo and tucatinib reshaped maintenance, some chemos are nearly gone, biomarkers guide us.
The right-sizing era for HER2+ BC has begun.
nature.com/articles/s41571-0… 🧵1/
SurvivorNet retweeted
Important study by @ldiaz1971 @MSKCancerCenter advocating for universal germline testing after a cancer diagnosis. Among ~40,000 patients, 18.4% of early-onset, 15.6% of average-onset, & 12.3% of late-onset cancers harbor pathogenic germline alterations.
aacrjournals.org/cancerdisco…
SurvivorNet retweeted
Comprehensive review article by Sara Hurvitz @fredhutch on state of the art advances in MBC treatment, published in @NEJM. This is also a timely reference for MDs and scientists and to cite in papers, grants, presentations. @SusanGKomen @BCRFcure @ASCO @AACR @PIK3CApathbreak
nejm.org/doi/full/10.1056/NE…
You don’t have to know exactly what to ask to get started.
SurvivorNet’s My Health Questions offers suggested questions tailored to the article you’re reading. Explore what comes next, ask follow-ups, and prepare for conversations with your care team, with SurvivorNet’s expert physician videos embedded in the answers.
Find questions to guide your next conversation: survivornet.com/my-health-qu…
SurvivorNet retweeted
A legend in the building. 🏈
Pro Football Hall of Famer, Super Bowl champion and New York Giants legend Harry Carson is sharing his story — both on the football field and through his experience with prostate cancer.
#ProPerspectives #ProstateCancerAwareness
SurvivorNet retweeted
The FDA has approved tucatinib (TUKYSA) in combination with trastuzumab and pertuzumab as first-line maintenance treatment for adults with HER2-positive metastatic breast cancer based on the Phase 3 HER2CLIMB-05 trial. Erika Hamilton, MD, presented the trial results at #SABCS25.
SurvivorNet retweeted
Today’s approval makes 11 in #breastcancer since May 1! Google “FDA oncology approvals” for searchable list of heme/oncology FDA approvals (2006 to now) w/ a concise description of each, in reverse chronological order. A+ for Boards prep or clinical practice. #OncTwitter #bcsm
Pretty stunning review on advances in breast cancer treatment in this week’s NEJM
So many new approvals since 2020 that they could only fit on a 2-page centerfold!!!
Looks like it’s the roaring 20s in breast cancer research!
#bcsm
